A Study of E6011 in Participants With Active Crohn's Disease

Summary

The primary purpose of this study is to examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind placebo-controlled trial.

Timeline

Start

2019-04-25

Primary completion

2022-03-16

Completion

2024-04-03

Outcome

Missed primary endpoint

registry analysis (superiority test); E6011 10 mg/kg vs Placebo Then E6011 10 mg/kg; Difference 10.3 (95% CI -24.9 to 45.4) NCT03733314 ↗

Drugs

Indications